by goldfishadmin | Oct 29, 2010 | News
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, announced today that a total of $622,971 in grants was awarded under the Qualifying Therapeutic Discovery Project (QTDP) program provided for in the Health Care and Education Reconciliation...
by goldfishadmin | Aug 10, 2010 | News
Orphagen Pharmaceuticals announced today that the National Cancer Institute (NCI) has awarded a Phase I SBIR grant to the Company for development of a new class of small molecule drugs for the treatment of adrenocortical and prostate cancer. The objective of the...
by goldfishadmin | Feb 1, 2010 | News
Orphagen Pharmaceuticals announced today that it has been awarded a two year federal grant to further characterize a novel class of small molecule drugs with potential to treat circadian rhythm sleep disorders and more serious psychiatric illnesses, such as anxiety,...
by goldfishadmin | Jan 7, 2009 | News
Orphagen Pharmaceuticals, Inc., a privately held company (“Orphagen”) today announced that it has entered into a Collaboration and License Agreement with Japan Tobacco Inc., (“JT”) to discover, develop and commercialize drugs in the areas of immunology and...
